Running against this, activation of CHEK2 has recently been shown to confer resistance to oxaliplatin treatment in colorectal cancer [85] and overexpression of CHEK2 was linked to worse survival in adrenocortical carcinoma [86]. Here, CHEK2 is linked to adrenal cortex carcinoma.